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CON S E N S U S S T A T EM EN T
Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date infor-
mation on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection
of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the
process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such
evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may
be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited prior to publication. The
authors are solely responsible for the content of the statements.
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Immune-mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is
associated with considerable morbidity and mortality. Treatment with various immu-
nosuppressive and antithrombotic drugs has been described anecdotally and in previ-
ous studies, but little consensus exists among veterinarians as to the optimal regimen
to employ and maintain after diagnosis of the disease. To address this inconsistency
and provide evidence-based guidelines for treatment of IMHA in dogs, we identified
and extracted data from studies published in the veterinary literature. We developed a
novel tool for evaluation of evidence quality, using it to assess study design, diagnostic
criteria, explanation of treatment regimens, and validity of statistical methods. In com-
bination with our clinical experience and comparable guidelines for humans afflicted
with autoimmune hemolytic anemia, we used the conclusions of this process to make
a set of clinical recommendations regarding treatment of IMHA in dogs, which we
refined subsequently by conducting several iterations of Delphi review. Additionally,
we considered emerging treatments for IMHA in dogs and highlighted areas deserving
of future research. Comments were solicited from several professional bodies to maxi-
mize clinical applicability before the recommendations were submitted for publication.
The resulting document is intended to provide clinical guidelines for management of
IMHA in dogs. These guidelines should be implemented pragmatically, with consider-
ation of animal, owner, and veterinary factors that may vary among cases.
Abbreviations: aPTT, activated partial thromboplastin time; BHS, bovine hemoglobin solution; DIC, disseminated intravascular coagulation; Hct, hematocrit; IMHA, immune-mediated hemolytic
anemia; IVIG, intravenous immunoglobulin; pRBC, packed red blood cells; RBC, red blood cell; RCT, randomized controlled trial; TDM, therapeutic drug monitoring; TPMT, thiopurine methyltrans-
ferase; UFH, unfractionated heparin.
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1 | INTRODUCTION
Despite recognition as a disease of dogs in 1957, immune-mediated
hemolytic anemia (IMHA) continues to claim the lives of up to half of
affected dogs.1–3 It is a prominent problem in a number of popular
breeds, including Cocker and Springer Spaniels, Old English Sheepdogs,
Bichon Frises, Bearded and Rough-coated Collies, Poodles, and Flat-
coated Retrievers.4 Treatment relies on nonspecific immune suppression
by glucocorticoids to control autoimmune responses targeting red blood
cell (RBC) antigens.3,5 Immunosuppressive treatment is associated with
a number of adverse effects that contribute to patient morbidity, both
by virtue of the drugs used and the prolonged duration of treatment. In
an endeavor to augment immunosuppression, and allow more rapid ini-
tial disease control and tapering of the glucocorticoid, a number of
second-line drugs have made their way into routine treatment of dogs
with IMHA, including azathioprine, cyclosporine, and mycophenolate
mofetil.2,5–7 Little consensus exists on either the specific drug or combi-
nation of drugs to use, or their dosages in individual patients.
A second component of treatment of IMHA in dogs is inhibition of
thrombosis, in particular pulmonary thromboembolism, which is a promi-
nent cause of morbidity and mortality.8–10 Various thromboprophylactic
regimens have been recommended, but overall consensus on the opti-
mal drug, or drugs, to administer in these cases has remained elusive.7,11
Furthermore, a number of supportive treatment strategies, such as
blood transfusion, gastroprotectants, and antimicrobial drugs, are admin-
istered on a case-by-case basis, often without clear consensus on when
and how they should be used. Emerging modalities offer promise for
more targeted, rapid, or durable treatment responses for IMHA in dogs
in the future, but there is an immediate need to provide therapeutic
guidelines for currently available drugs.
The objective of this Consensus Statement therefore is to present
recommendations for the treatment of IMHA in dogs, considering all
of the available evidence as well as expert opinion. It focuses on
immunosuppressive and thromboprophylactic drugs, but also con-
siders supportive and emerging treatment modalities, during both the
initial stabilization of patients and their long-term management. It also
provides recommendations for future research in this area.
2 | MATERIALS AND METHODS
An extended methods section is available in Supporting Information S1.
2.1 | Scope of the work
Consensus statements are intended to produce clinical guidelines on
contentious topics, particularly when a paucity of published data is
available to inform clinical decisions. Such guidelines are produced
when a panel of qualified individuals reaches agreement using what-
ever resources are available to them. In approaching this work, we
chose to conduct a systematic review of epidemiological evidence
investigating associations between therapeutic interventions and out-
come in dogs with IMHA but, where published data were lacking, we
also decided to take advantage of clinical experience, guidelines used
in human medicine, and experimental studies. Our recommendations
are intended to act as guidance for clinicians managing dogs with
IMHA and should be implemented with consideration of patient, cli-
ent, and veterinary factors that may vary among cases.
2.2 | Literature review
We searched 3 scientific databases (MEDLINE/PubMed, ISI Web of Sci-
ence [Core Collection and BIOSIS Citation Index], and CAB Abstracts) in
December 2017 using search strategies shown in Supporting Informa-
tion S1. We excluded all references published before 1980, but included
those published in languages other than English. All references were
copied to reference management software (EndNote X8; Clarivate Ana-
lytics, Philadelphia).
2.3 | Curation of records
We removed duplicate records and then scanned the remaining
abstracts to remove references that did not provide information on
IMHA, did not contain primary data, reported data from a species other
than the dog, described data from <5 dogs, or were duplicated in a later
study. We obtained the full text of the remaining references and
excluded those not providing information on therapeutic interventions
and at least 1 direct outcome measure for dogs with primary IMHA. A
total of 46 papers remained after this process, to which a newly pub-
lished paper was added in March 2018. Of these 47 references, 7 were
translated into English (from German, n = 6; and French, n = 1). The
process used to curate references is illustrated in Figure 1.12
2.4 | Quality assessment
We designed a novel quality assessment and data extraction tool for
those studies investigating the effect of ≥2 therapeutic interventions
on outcome in dogs with IMHA; studies describing a single interven-
tion were categorized as “descriptive association only.” The quality
assessment tool included 4 domains intended to assess the rigor of
study design, diagnostic criteria for IMHA, explanation of treatment
protocols, and validity of statistical methods. An additional domain
related to masking, randomization, and intention-to-treat analysis was
included for randomized controlled trials (RCTs), and the fragility index
was calculated if sufficient data were available and for studies reporting
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a significant difference in a binary outcome (ClinCalc Fragility Index
Calculator. 2019. https://clincalc.com/Stats/FragilityIndex.aspx. Accessed
July 2, 2018).13 The treatment protocols, major outcome measures, and
results of any statistical tests also were recorded for each paper. The tool
was tested by all members of the panel using the same 2 papers, from
which feedback informed the final version (shown in Supporting Informa-
tion S2).
The papers for review were assigned randomly to members of the
panel, such that each paper was reviewed by 2 different panel members;
no panel member reviewed a paper to which they had contributed.
Where differences were identified between the 2 reviewers of a paper,
these were resolved by consensus before all of the results were pooled
into a single spreadsheet (Supporting Information S3). Variation in statisti-
cal methods and outcome measures precluded quantitative meta-analysis.
The quality scores for individual questions within each domain
were summated to produce scores for this domain for each paper;
results of these assessments are shown in Figures 2, 4, 5, and 8, with
associated summaries in Tables 1, 3–5.
2.5 | Delphi process
Each panel member drafted initial recommendations, with reference
to the results of the quality appraisal; these were assembled to
produce a working template for the Consensus Statement. The draft
recommendations then were subjected to 4 rounds of Delphi review
in their entirety, using an anonymized online questionnaire (Survey
Monkey, San Mateo, California). At the conclusion of each round, sug-
gestions were incorporated into the working template by 1 facilitator,
and a transcript of all written comments was provided to each panel
member. After 3 rounds of review, several outstanding differences
were resolved in a meeting of all panel members before the recom-
mendations were presented at the American College of Veterinary
Internal Medicine (ACVIM) Forum on June 14, 2018 in Seattle,
Washington.
2.6 | Determination of the strength of
recommendations
The template outlined in the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) guidelines28,29 (shown in Support-
ing Information S1) was used to classify the strength of each recommen-
dation as either “weak” or “strong.” To achieve this objective, every panel
member assessed each recommendation according to 4 domains: bal-
ance of expected beneficial and harmful effects, strength of evidence,
expected stakeholder values and preferences, and expected cost. Rec-
ommendations were considered “strong” if ≥5 panel members reached
F IGURE 1 Flow diagram indicating
flow of information used in the systematic
review. Diagram produced using the
Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)
statement12
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this decision; all other recommendations were considered “weak.” The
decisions of panel members are shown in Supporting Information S1.
All “strong” recommendations were phrased with the conjugated
verb “we recommend,” whereas “weak” recommendations were phrased
with “we suggest.”
2.7 | Production of the Consensus Statement
The working document was further edited to incorporate comments
generated during oral presentation, before submission to ACVIM for
review by all members. The draft Consensus Statement also was sub-
mitted to the European College of Veterinary Internal Medicine,
American College of Veterinary Emergency and Critical Care, and
European College of Veterinary Emergency and Critical Care for solici-
tation of comments from members. Feedback from these specialist
colleges was used by the panel members to modify the Consensus
Statement, producing a final version that was submitted to the Journal
of Veterinary Internal Medicine.
In the text of the Consensus Statement, we make specific recom-
mendations, followed by the strength of recommendation and our
rationale. We have applied the principles of evidence-based medicine,
but in all cases expert opinion, coupled with inferences from parallel
data from human medicine (when available30), was an integral part of
the process.
3 | RESULTS AND RECOMMENDATIONS
3.1 | Timing of treatment
1. We recommend introducing immunosuppressive interventions after
all diagnostic samples have been collected, provided doing so does
not unduly delay institution of treatment.
Strength of recommendation: Strong
Rationale
There is limited evidence to suggest that treatment with prednisone
for variable periods of time will not affect the result of a direct anti-
globulin test,31 but the effect of other immunosuppressive drugs on
this and other tests has not been investigated in dogs. Administration
of some drugs, particularly glucocorticoids, may limit the ability to
detect underlying diseases, such as lymphoma. Therefore, diagnostic
evaluation should be expedited in cases in which underlying cancer or
infectious diseases are suspected. Further guidance is available in the
Consensus Statement on Diagnosis of Immune-Mediated Hemolytic
Anemia in Dogs and Cats.32
3.2 | Blood typing and cross-matching
An expanded version of this section, with further commentary and
discussion of underlying evidence, is available in Supporting Informa-
tion Appendix A1.
2. We recommend that clinicians consider the effect of autoaggluti-
nation on the results of cross matching and blood typing, and seek
guidance from manufacturers of test kits.
Strength of recommendation: Strong
3.3 | Blood transfusion and blood products
3. We recommend administering packed red blood cells (pRBC) when
dogs with IMHA display clinical features attributable to decreased
tissue oxygen delivery. If pRBC are not available, administration of
whole blood is a reasonable alternative.
Strength of recommendation: Strong
Rationale
Review of the literature did not identify any studies reporting an asso-
ciation between the number or volume of pRBC or whole blood trans-
fusions with mortality in dogs with IMHA. The decision to transfuse
should depend on factors specific to the individual patient, including
severity of clinical signs, blood lactate concentration at rest,33 normal
PCV/hematocrit (Hct) expected in the breed, speed of onset of ane-
mia, and availability of patient monitoring and supportive care. The
PCV to trigger transfusion for a sighthound with acute onset disease
therefore would be higher than for a Labrador Retriever with insidious
onset anemia, and transfusion would be considered earlier for a
patient with progressive anemia that cannot be hospitalized for inten-
sive monitoring. In the absence of clinical signs, some (2/8) panel
members recommended transfusing dogs with a PCV/Hct <12%, whereas
the remainder of the panel did not have a numerical trigger. Dogs with
IMHA typically are euvolemic, making pRBC preferable to whole blood
because the plasma provides no added benefit, increases the risk of vol-
ume overload, andmay increase the risk of transfusion reaction.
4. Fresh pRBC, ideally no older than 7-10 days, are recommended
for use in dogs with IMHA. If these are not available, older units
may be used but may be associated with a greater risk of compli-
cations and increased mortality.
Strength of recommendation: Strong
Rationale
Increasing age of pRBC was associated with increased risk of mortality
in dogs with hemolysis, of which 90% were reported to be dogs with
IMHA.34 The conclusion of this retrospective study was limited by the
absence of information on diagnosis of IMHA and a lack of methodo-
logic detail on statistical analysis. A more recent retrospective study
also reported an increased risk of hemolytic transfusion reactions with
increasing age of the transfused pRBC.35
5. We recommend administering pRBC or whole blood in preference
to bovine hemoglobin solutions (BHS).
Strength of recommendation: Strong
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Rationale
Administration of products containing intact erythrocytes represents a
more physiologic solution for improving oxygen-carrying capacity in
dogs for several reasons. First, BHS scavenge nitric oxide, potentially
activating platelets and causing vasoconstriction, which increases risk
of hypertension.36 Second, BHS exert a greater colloid osmotic (oncotic)
pressure than do RBCs, increasing the risk of intravascular volume
expansion and hypertension.37 Transfused RBCs also are likely to have
a longer circulating half-life than BHS, although the half-life of trans-
fused RBCs is difficult to estimate in dogs with active hemolysis.38
Furthermore, in 1 study, administration of a BHS (HB-200) was
associated with an increased relative risk of mortality.18 Whether
this increased risk was because of the solution itself or confounding
factors, such as variation in disease severity between treatment
groups, was unclear. Only a single direct comparison of BHS and
pRBC has been undertaken in dogs during an RCT comparing admin-
istration of the 2 products for stabilization of dogs with babesiosis.
No difference in recovery of acid/base and perfusion variables was
found, but those dogs receiving pRBC had a faster clinical
recovery.39
In conclusion, BHS could be administered if pRBC or whole blood
are not available. However, BHS currently is unavailable in many
countries, including the United States.
6. We do not recommend administering fresh frozen plasma rou-
tinely to dogs with IMHA.
Strength of recommendation: Strong
Rationale
Features of disseminated intravascular coagulation (DIC) have been
described in up to 45% of dogs with primary IMHA; DIC therefore has
been suggested as a risk factor for thromboembolic disease.8,40–42 Based
on guidelines in human medicine, there is little indication for plasma
transfusions in nonhemorrhagic DIC patients not requiring invasive pro-
cedures.43 Similarly, as summarized below and in Table 1 and Figure 2,
clinical data do not support routine administration of plasma to dogs
with IMHA.
In addition to standard treatment (including other blood products,
heparin, and immunosuppressive drugs), administration of a single
dose of fresh frozen plasma to dogs with IMHA did not decrease
mortality or occurrence of thromboembolic events, or produce any
improvement in plasma antithrombin concentration.15 The conclusion
of this study is subject to bias because it compared cohorts that were
separated in time. A further study reported that the volume of plasma
administered to IMHA non-survivors was greater than that adminis-
tered to survivors at 14 days after diagnosis.14 The authors con-
cluded that administration of plasma was unlikely to be the cause of
death because this association probably was confounded by other
factors, including coagulation status of the dogs and prevalence
of DIC. T
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3.4 | Immunosuppressive treatment
Our recommended approach is summarized in Figure 3. Failure to
respond to treatment as expected should prompt consideration of
whether criteria for diagnosis of nonassociative (primary) IMHA have
been fulfilled, as outlined in the Consensus Statement on Diagnosis of
Immune-Mediated Hemolytic Anemia in Dogs and Cats.32
7. We recommend that prednisolone or prednisone at an initial PO dos-
age of 2-3 mg/kg/day, or 50-60 mg/m2/day for dogs >25 kg, be
introduced after a diagnosis of IMHA has been reached. The drug
may be administered as a single daily dose or divided into 2 daily
doses. Dexamethasone (0.2-0.4 mg/kg/day) may be administered IV
on a temporary basis if the patient initially will not tolerate PO drug
treatment.
Strength of recommendation: Strong
Rationale
The dosage range for prednisone or prednisolone is based on review
of published literature and clinical experience, with some panel mem-
bers (2/8) recommending that the initial dosage of prednisone or pred-
nisolone not exceed 2 mg/kg/day, or 40 mg/m2/day for dogs >25 kg,
owing to the risk of more severe adverse effects with higher dosages.
Review of published literature, including a study population treated with
prednisolone alone, indicated an initial response rate of approximately
80%, but did not find any evidence to suggest that IV dexamethasone is
superior to PO prednisone or prednisolone.2,5,18–21,24,25,44–46 Studies
supporting previous statements that prednisolone may be more effec-
tive47 or less irritating to the gastrointestinal tract48 if given twice daily
currently are lacking. Human medical literature suggests that once daily
administration may be associated with fewer adverse mineralocorticoid
effects.49
8. If the starting dosage of prednisone or prednisolone is >2 mg/kg/day,
we recommend that it be decreased to ≤2 mg/kg/day within the first
1-2 weeks of treatment, provided the dog is responding to treat-
ment, as demonstrated by a stable or increasing PCV/Hct.
Strength of recommendation: Strong
Rationale
This recommendation is based on clinical experience, suggesting that
more severe adverse effects are observed if high dosages of glucocor-
ticoids are used for prolonged periods.
9. We suggest that a second immunosuppressive drug may be intro-
duced in any dog from the outset of treatment in an effort to decrease
the dosage of glucocorticoid required. In particular, we suggest treat-
ing with 2 immunosuppressive drugs in the following situations:
 The dog has clinical features at presentation consistent with
severe or immediately life-threatening disease.
 The PCV/Hct does not remain stable, with an absolute decrease
of ≥5% within 24 hours, during the first 7 days of treatment with
a glucocorticoid drug as described in #7 above.
 The dog has continued to be dependent on blood transfusions
after 7 days of treatment as described in #7 above.
 The dog develops or, based on previous treatment, is expected
to develop severe adverse effects related to the use of gluco-
corticoids at any time during its treatment. This is of particular
relevance for dogs >25 kg in body weight.
Strength of recommendation: Weak
Rationale
These recommendations are largely based on clinical experience of the
panel. The decrease of 5 percentage points in PCV/Hct (eg, from 25% to
20%) is intended to account for variations in these variables because of
changes in hydration status or measurement error. Definitions of “steroid
failure” are modified from several studies suggesting a poor response
if an unstable PCV/Hct or persistent agglutination remain after
7-14 days.8,15,26,27,50 We recommend introducing 2 drugs in dogs with
severe disease from the outset because some dogs may show an inade-
quate response to a single agent. Introducing 2 drugs simultaneously
increases the chance that an individual dog with life-threatening disease
will receive a drug to which it will show a favorable response in the critical
early phase of treatment. Numerous studies have evaluated possible
prognostic factors for dogs with IMHA, either by exploring associations
between survival and a single candidate variable, or by constructing a
multivariable model to account for possible confounding factors. Among
the latter models, increased serum bilirubin concentration (or clinical
icterus) and increased serum urea or BUN concentration were identified
F IGURE 2 Results of evidence quality
assessment for studies investigating the
use of blood products in dogs with
immune-mediated hemolytic anemia
(IMHA). RCT, randomized controlled trial
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as independent predictors of mortality in 2 studies of different patient
populations.51 Both prognostic factors subsequently were identified by a
further study of dogs with IMHA in the United Kingdom.52 We suggest
therefore that evaluation of serum bilirubin and urea concentrations may
be of greatest utility in predicting outcome for dogs with IMHA (pub-
lished values shown in Table 2), although several other factors have been
identified as single predictors.53
10. Where a second drug is administered for treatment of IMHA in dogs,
we suggest 1 of the following options (listed in alphabetical order):
 Azathioprine: 2 mg/kg or 50 mg/m2 PO q24h. After 2-3
weeks, the dosing interval may be increased to every other
day until treatment is discontinued.
 Cyclosporine: 5 mg/kg PO q12h. Adjustment of this dosage
may be guided by therapeutic drug monitoring (TDM) (see
recommendation #28).
 Mycophenolate mofetil: 8-12 mg/kg PO q12h
If these drugs are not available or tolerated, the following drug
may be used, but its use is supported by less evidence than
those listed above:
F IGURE 3 Flow diagram showing
recommended approach for initial
treatment of dogs with immune-
mediated hemolytic anemia (IMHA).
IVIG, intravenous immunoglobulin;
TDM, therapeutic drug monitoring.
Various outcomes make reference to
Consensus Summary Statement #14,
to which the reader is referred for
further information
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 Leflunomide: 2 mg/kg PO q24h. Adjustment of this dosage
may be guided by TDM (see recommendation #28).
Strength of recommendation: Weak
Rationale
The benefit of adding a second drug has not been established. Case
selection bias probably exists in the available (primarily retrospective)
studies, with more severely affected patients often receiving addi-
tional immunosuppressive treatment. Prospective studies to establish
definitively the superiority of any of the second-line immunosuppres-
sive treatments are lacking. A summary of our review of studies com-
paring ≥2 treatment protocols for dogs with IMHA is shown in
Table 3, with appraisal of the evidence quality of these articles in
Figure 4.
Azathioprine Two previous studies suggested that administration of
azathioprine may be associated with a more favorable outcome.16,17
In the first, a retrospective cohort study, inclusion of azathioprine in
the treatment regimen alongside prednisone and cyclophosphamide
was associated with improved survival using Kaplan-Meier analysis
with log rank test.16 However, this conclusion was limited by incom-
plete information on the treatment protocols (Figure 4). In the second,
a case series of dogs with IMHA and severe thrombocytopenia, dogs
that received azathioprine (in combination with other drugs) were
4.27 times more likely to survive to 30 days after initiation of treat-
ment compared to dogs that did not receive the drug, although the
authors speculated that administration was more likely to have been a
marker of survival (because dogs survived long enough to receive a
second agent) than its cause.17 This study was limited by incomplete
presentation of survival information for each group (Table 3). Two fur-
ther studies have suggested a possible favorable effect of azathioprine
on survival, but associations between drug and outcome were limited
in both analyses by the small numbers of patients (Table 3).5,20 A final
study reported no difference in outcome between dogs treated with
azathioprine and prednisolone compared to a historical control popu-
lation that received prednisolone alone.2 Although the appraisal of
this study was relatively favorable (Figure 4), the conclusion may be
biased because the 2 cohorts of dogs were separated in time and dif-
fered with respect to other variables that the authors previously had
identified as markers of a poor prognosis.54
Cyclosporine Administration of cyclosporine to dogs with IMHA is
reported in numerous studies.5,7,18,26,27,52,55 In 1 retrospective cohort
study, the use of cyclosporine (in combination with other drugs) did
not change the relative risk of death compared to all other treatment
protocols that excluded the drug, although this study was limited by
incomplete description of the treatment regimens (Figure 4).18 A fur-
ther retrospective study found no difference in mortality at 1 month
or 1 year after diagnosis in dogs treated with prednisolone alone and
those treated with prednisolone and cyclosporine, although this
study also was limited by incomplete description of treatment regi-
mens and less rigorous inclusion criteria (Figure 4).5 A double-masked
randomized clinical trial comparing prednisone alone to prednisone
and cyclosporine for treatment of dogs with IMHA was reported in
abstract form only, but found no difference in survival between
groups.56
Mycophenolate mofetil Use of mycophenolate has been reported in
several recent studies.6,23,27,50,52,55 One study documented similar
efficacy of a protocol combining mycophenolate with prednisone
compared to prednisone combined with another immunosuppressive
drug (azathioprine or cyclosporine) for treating IMHA (Table 3),
although this was a retrospective cohort study, with no randomiza-
tion of dogs to either treatment regimen and with undetermined sta-
tistical power for comparison of outcome between treatment groups
(Figure 4).6
Leflunomide Leflunomide is reported for the treatment of various
refractory immune-mediated diseases in dogs, including IMHA,57 and
as a second-line drug for the treatment of IMHA.27,55,58 No prospec-
tive or retrospective studies have compared its efficacy to other, more
commonly used, second drugs, or to prednisone or prednisolone
alone.
11. We recommend that cyclophosphamide not be administered to
dogs with IMHA.
Strength of recommendation: Strong
Rationale
Review of published literature found evidence that cyclophosphamide
treatment offered no benefit over treatment with glucocorticoids
alone, and even could be detrimental to long-term prognosis.18–20
However, 1 study was limited by the absence of a sample size calcula-
tion and by failure to report any statistical comparison of survival in
the 2 treatment groups (Table 3, Figure 4).19 A retrospective cohort
study also was limited by lack of information on possible variability in
enrolled cases and by incomplete information relating to treatment
regimens (Figure 4).18
12. Administration of IV immunoglobulin (IVIG) at a dosage of 0.5-1
g/kg as a single infusion may be considered as a salvage measure
in dogs not responding to treatment with 2 immunosuppressive
drugs, but we do not recommend it for routine treatment.
Strength of recommendation: Strong
Rationale
Administration of IVIG may appear to be an attractive prospect
because it is suggested to act quickly, but several studies showed no
effect of this treatment on survival when compared to other immuno-
suppressive regimens in dogs with IMHA (Table 4).18,21–25,59 The
design and risk of bias varied among these studies, but all supported
the same conclusion (Figure 5). Studies have indicated that adminis-
tration of IVIG may be associated with more rapid recovery of a
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normal PCV,22,60 or a lesser requirement for transfusions,61 but 2 of
these studies did not include a control group,60,61 and the other con-
tained a number of statistical anomalies22 (Figure 5). Nevertheless,
this evidence base may provide a rationale for use of IVIG as a salvage
option in cases unresponsive to the treatments described in recom-
mendations #7-10. In people, the recommended dosage of IVIG is
0.4-0.5 g/kg/day administered for 4-5 days,30 but the efficacy and
safety of treatment beyond 3 days has not been assessed in dogs.
Availability of IVIG is limited in many countries, and it is expensive.
Our recommended approach to management of refractory patients is
shown in Figure 3.
13. We suggest that the use of ≥3 immunosuppressive drugs at the
same time should be avoided.
Strength of recommendation: Weak
Rationale
This recommendation is based on clinical experience suggesting that
combinations of ≥3 drugs rarely are required for management of
IMHA and on published data indicating that some combinations are
associated with more severe adverse effects, including an increased
risk of opportunistic infections.62,63 Also, no published evidence is
available to demonstrate that combinations of multiple immunosup-
pressive drugs are associated with more effective control of disease.
Our recommended approach to management of refractory patients is
shown in Figure 3. If ≥3 drugs are administered simultaneously under
this scheme, we recommend using drugs that target different immune
pathways, which would preclude concurrent administration of azathi-
oprine and mycophenolate mofetil.
14. When the PCV/Hct has remained stable and >30% for 2 weeks
after commencing treatment, with improvement in the majority of
measures of disease activity (including spherocytosis, agglutination,
serum bilirubin concentration, and reticulocyte count), we re-
commend decreasing the dosage of prednisone or prednisolone
by 25%.
If a second drug has been introduced with the aim of limiting
glucocorticoid-related adverse effects, the dosage of this drug
should not be changed, but a greater reduction in the dose of
prednisone or prednisolone (of 25%-50%) may be possible if the
dog shows an adequate response to treatment.
Strength of recommendation: Strong
Rationale
This recommendation is based on clinical experience of the panel. One of
the 8 panel members suggested that the serum bilirubin concentration
should normalize before any dose reduction is made. Alternatively, if a
dog is receiving prednisone or prednisolone in combination with another
immunosuppressive drug, the dosage of the non-glucocorticoid drug
could be decreased in increments before changing the dosage of predni-
sone or prednisolone if the non-glucocorticoid drug appears to be causing
more adverse effects or is associated with unsustainable cost. However,
in general, we recommend decreasing the dosage of prednisone or pred-
nisolone first because glucocorticoids are associated with more prevalent
and dose-related adverse effects (see recommendation #18 below).
F IGURE 4 Results of evidence quality
assessment for studies investigating the use
of immunosuppressive drugs in dogs with
immune-mediated hemolytic anemia
(IMHA). RCT, randomized controlled trial
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15. Provided the PCV/Hct remains stable and >30%, with improve-
ment in the majority of measures of disease activity (including
spherocytosis, agglutination, serum bilirubin concentration, and
reticulocyte count), we recommend decreasing the dose of pred-
nisone or prednisolone by 25% every 3 weeks.
If a second drug has been introduced with the aim of limiting
glucocorticoid-related adverse effects, the dosage of this drug
should not be changed, but a greater reduction in the dose of
prednisone or prednisolone (of 25%-33%), or a shorter interval
between reductions (2 weeks), may be possible if the dog shows
a good response to treatment.
A typical duration of 3-6 months of treatment is expected for
prednisone or prednisolone in the majority of cases, with an
expected duration of 4-8 months for all immunosuppressive
treatment.
Strength of recommendation: Strong
Rationale
This recommendation is based on clinical experience of the panel.
One of the 8 panel members suggested that the serum bilirubin con-
centration should normalize before further dose reductions are made.
16. After stopping prednisone or prednisolone, we suggest 1 of the
following options in dogs also receiving another immunosuppres-
sive drug:
 Continue to administer the other immunosuppressive drug at
the same dosage for 4-8 weeks, then stop without tapering.
 Taper the dosage of the other immunosuppressive drug in the
same way as for the prednisone or prednisolone, as described
in #15 above.
Strength of recommendation: Weak
Rationale
This recommendation is based on the clinical experience of the panel,
with no published evidence to indicate which approach will result in a
better outcome. Among the panel, 4/8 members currently adopt the
first approach described above, 3/8 adopt the second approach, and
1/8 stops administering the second immunomodulatory drug at the
same time as the prednisone or prednisolone is stopped, without
tapering.
17. At a minimum, we recommend assessing the PCV/Hct before
any dose reduction to ensure continued response to treatment.
These variables should be assessed every 1-3 weeks during
treatment. Additional tests to evaluate disease activity, including
assessment for spherocytes, agglutination, and increased serum
bilirubin concentration, also are recommended periodically to
ensure continued response to treatment.
Strength of recommendation: Strong
Rationale
This recommendation is based on clinical experience of the panel.
3.5 | Monitoring for adverse effects associated with
immunosuppressive treatment
18. Glucocorticoids: We recommend careful physical examination and
review of owner observations in dogs receiving glucocorticoids
to assess the severity of adverse effects. Urinalysis, with or with-
out bacterial culture, may be considered every 8-12 weeks and
is recommended if clinical features suggest urinary tract infec-
tion. We recommend obtaining baseline values for biochemical
variables that may be affected by glucocorticoids before starting
treatment with these drugs or any potentially hepatotoxic drugs.
Strength of recommendation: Strong
F IGURE 5 Results of evidence
quality assessment for studies
investigating the use of intravenous
immunoglobulin in dogs with immune-
mediated hemolytic anemia (IMHA).
RCT, randomized controlled trial
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Rationale
The high frequency of adverse effects associated with initial immuno-
suppressive dosages of glucocorticoids in dogs with IMHA, and their
potential impact on owner willingness to pursue treatment, should not
be underestimated. However, remarkably little information regarding
glucocorticoid adverse effects is available in studies of dogs with
IMHA, with polyuria and polydipsia reported in 29% of patients receiv-
ing glucocorticoids in 1 investigation.5
In 1 recent prospective study of dogs with inflammatory bowel
disease, the following adverse effects were noted in the group of
dogs receiving prednisone (at 1 mg/kg PO q12h): polydipsia (80% of
treated dogs), polyuria (70%), excessive panting (55%), and lethargy
(30%), with muscle weakness or atrophy, urinary incontinence, and
temperament change reported less commonly.64 Adverse effects
were rated as moderate to severe in 30% of prednisone-treated
dogs.64 In a different study of dogs with immune-mediated polyar-
thritis, the following adverse effects were observed in dogs receiving
prednisone after 45 days of therapy, after starting treatment at
1 mg/kg twice daily and with doses tapered by 25% every 2-3 weeks
when in remission: polydipsia (100% of treated dogs), polyphagia
(100%), polyuria (91%), and panting (81%), with an approximately
50% reduction in the prevalence of most of these adverse effects by
3 months.65
Other long-term adverse effects include alopecia; thin skin; cal-
cinosis cutis; susceptibility to bruising; muscle atrophy; fat redistri-
bution to the abdomen with a resulting pot-bellied appearance;
hepatomegaly; predisposition to pyoderma, demodicosis, and uri-
nary tract infections; and exacerbation of congestive heart failure.66
Predisposition to diabetes mellitus and pancreatitis also is sus-
pected to be associated with chronic glucocorticoid treatment.67–69
Commonly observed clinicopathologic abnormalities include a stress leu-
kogram and increased serum alkaline phosphatase (ALP) activity, with
occasional polycythemia, thrombocytosis, hyperlipidemia, and hypergly-
cemia. Similar adverse effects are observed in human patients treated
with glucocorticoids.70
Subclinical bacteriuria is common in dogs on long-term glucocorticoid
treatment, but the clinical relevance of this finding is uncertain,71,72 with
no published data available to determine whether treating, or not treat-
ing, affected dogs will result in a more favorable outcome. Guidelines for
treatment of urinary tract infection in dogs suggest antimicrobials could
be considered in immunocompromised patients with subclinical bacteri-
uria because of the risk of ascending or systemic infection,73 although
comparable guidelines for human patients refrain from making any rec-
ommendation on this topic because of a lack of clinical evidence.74 We
therefore suggest periodic urinalysis in dogs treated with glucocorticoids,
with or without bacterial culture. If clinical signs are observed or an
active sediment associated with bacterial growth is found, we recom-
mend appropriate antimicrobial treatment. If bacterial growth without
active sediment is found in the absence of clinical signs, we do not make
any recommendation regarding treatment, but, if treatment is not imple-
mented, we recommend more frequent review of clinical signs and uri-
nalysis results owing to the risk of ascending infection.
19. Azathioprine: We recommend that CBCs and relevant serum bio-
chemical variables (especially alanine aminotransferase [ALT] activity)
be monitored every 2 weeks during the first 2 months of treatment,
and then every 1-2 months until treatment is discontinued.
Strength of the recommendation: Strong
Rationale
The standard starting dosage of azathioprine (2 mg/kg/day) in dogs
usually is well tolerated. Gastrointestinal adverse effects such as nau-
sea, anorexia, vomiting, and diarrhea occasionally are reported but
typically are mild and self-limiting. Azathioprine can, however, also
cause severe hepatotoxicity or marked myelosuppression in some
dogs.75,76
Hepatotoxicity (typically characterized by a reversible increase in
serum ALT activity in the absence of clinical signs) occurs in approxi-
mately 15% of German Shepherd dogs75 and may be more common in
German Shepherds. Hepatotoxicity usually develops in the first few
weeks of treatment; if the drug is well tolerated for the first 2 to
4 weeks, it tends to be well-tolerated in the long-term.75 Glucocorti-
coid treatment causes increases in serum ALT and ALP activity; the
effects of azathioprine therefore may be difficult to distinguish from
the effects of glucocorticoids. In general, an increase in ALT activity
that approaches or exceeds the magnitude of increase of ALP should
prompt concern.
Although marked myelosuppression is uncommon, chronic azathio-
prine usage sometimes causes mild to moderate poorly regenerative ane-
mia.77 Myelosuppression, in contrast to hepatotoxicity, can be delayed
and occur months into treatment.75,77 Marked myelosuppression and
hepatotoxicity appear to be idiosyncratic non-dose-dependent reactions
and typically are reversible if the problem is recognized early enough,
and azathioprine is discontinued. Several individual case reports also
have described pancreatitis in dogs receiving azathioprine, but cause and
effect have not been established.78,79 Deficiencies in a key enzyme
involved in azathioprine metabolism, thiopurine methyltransferase (TPMT),
can cause azathioprine toxicity in cats and people. Although TPMT expres-
sion in dogs is variable, TPMT deficiency does not appear to be associated
with the severe toxicities sometimes seen in dogs.76,80
20. Cyclosporine: We recommend that dogs receiving cyclosporine
be monitored for gastrointestinal adverse effects and gingival
overgrowth. Relevant biochemical variables should be evaluated
every 2-3 months owing to the risk of hepatotoxicity in a small
proportion of dogs.
Strength of recommendation: Strong
Rationale
Adverse effects are uncommon with cyclosporine treatment in dogs,
with the exception of gastrointestinal signs such as vomiting, diarrhea,
anorexia, and nausea.81 Administering the medication frozen or with
food can decrease gastrointestinal adverse effects,82 although admin-
istration with food carries a risk of altering drug absorption profiles.
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Uncommonly, cyclosporine may cause idiosyncratic hepatotoxicity,
which does not seem to be dose-dependent; gingival hyperplasia and
hypertrichosis also have been reported occasionally.83–87 Nephrotoxi-
city is a potential problem in people receiving cyclosporine, but clini-
cally relevant renal damage has not been documented in dogs at
standard dosages.87,88
An advantage of cyclosporine as an immunosuppressive drug is that
it is not myelosuppressive. However, susceptibility to opportunistic infec-
tions and subclinical bacteriuria have been reported, particularly in com-
bination with glucocorticoids and other immunosuppressive drugs.72,89,90
Cyclosporine is metabolized by the hepatic cytochrome P-450 system;
inadvertent drug overdosage therefore is possible if cyclosporine is given
concurrently with drugs that inhibit P-450 enzymes. Ketoconazole has
been used to decrease PO cyclosporine dosages in dogs by as much as
75%, although individual responses vary.91,92 Experimentally, PO cyclo-
sporine increases some markers of platelet activation in normal dogs,
which may be a concern in dogs with IMHA, in which hypercoagulability
and thromboembolism may be major contributors to patient mortality.93
However, the clinical relevance of this phenomenon remains unclear.
21. Mycophenolate mofetil: We suggest that dogs should be monitored
for gastrointestinal adverse effects. We also suggest that CBCs
should be monitored every 2-3 weeks for the first month of treat-
ment with mycophenolate mofetil, then every 2-3 months until
treatment is discontinued.
Strength of recommendation: Weak
Rationale
Although the most commonly used form of mycophenolate (mycopheno-
late mofetil) is generally well tolerated in dogs, gastrointestinal adverse
effects can sometimes limit the use of the drug.6,50,94–98 In some cases,
ulcerative colitis may develop that warrants discontinuation of the drug.
Recommended starting dosages for mycophenolate mofetil in dogs have
varied from 10 to 20 mg/kg PO q12h, but gastrointestinal signs at the
higher end of the dosage range often will necessitate dose reductions.
Reported prevalence of diarrhea can be ≥20%, and may be delayed for
1-2 weeks after starting treatment.6,50,94–98 Generally, starting dosages
of 7-10 mg/kg PO q12h (14-20 mg/kg total daily dose) are associated
with a much lower prevalence of diarrhea.99,100 In stable patients, there-
fore, a starting dosage of 8-12 mg/kg q12h is recommended. If diarrhea
occurs, it often is responsive to dose reduction.96,98
In people, gastrointestinal signs, hepatotoxicity, and, less commonly,
marked myelosuppression as well as a rare and fatal progressive multifo-
cal leukoencephalopathy have been reported.101,102 Unlike in humans,
mycophenolate has not been reported to cause hepatotoxicity in dogs,
and thus the benefit of monitoring biochemical profiles is questionable.
However, mycophenolate potentially is myelosuppressive, hence the rec-
ommendation to monitor CBCs.
22. Leflunomide: We suggest that CBCs and relevant serum biochem-
ical variables (especially ALT and ALP activities) be monitored
every 2 weeks for the first 2 months in dogs receiving lefluno-
mide, and then every 1-2 months until treatment is discontinued.
Strength of recommendation: Weak
Rationale
Leflunomide appears to be well tolerated in dogs, but its use has been
limited in veterinary medicine compared to other drugs.57,103 Occasional
more serious adverse effects such as cutaneous drug reactions, hepato-
toxicity, and pulmonary lesions (as found in human patients) may be rec-
ognized in dogs in the future. The most common adverse effects
reported with leflunomide administration in dogs are occasional inappe-
tence, lethargy, vomiting, and diarrhea.57,58,104 However, a recent study
also reported increased liver enzyme activity in approximately half of
treated dogs (although it was difficult to separate this finding from the
effect of concurrent glucocorticoid administration) and several instances
of severe myelosuppression.104 Although recommended oral dosages
for leflunomide in dogs ranged from 3 to 4 mg/kg/day in the earlier
literature,103,105 a starting dosage of 2 mg/kg PO q24h appears to be
efficacious, with possible lower risk of adverse effects.58
3.6 | Management of drug-associated
myelosuppression
An expanded version of this section, with further commentary and
discussion of underlying evidence, is available in Supporting Informa-
tion Appendix A2.
23. As soon as myelosuppression is documented, we recommend
that the causative drug be discontinued.
Strength of recommendation: Strong
24. For management of asymptomatic neutropenic patients, we rec-
ommend that, if the neutrophil count is between 1000 and 3000
cells/μL, antibiotics not be administered unless other indepen-
dent risk factors for infection are present. When the neutrophil
count is <1000 cells/μL, prophylactic antibiotics are indicated.
We recommend close observation for any change in vital signs,
demeanor, or development of new gastrointestinal signs, which
could signal the onset of sepsis.
Strength of recommendation: Strong
25. We make the following recommendations for management of
symptomatic neutropenic patients:
• Identify a source of infection, if possible.
• Institute parenteral, 4-quadrant antibiotic coverage, with reference
to any known organ dysfunction. Antibiotics may be required at the
high end of the recommended dosage range to offset decreased
organ perfusion in sepsis.
• Institute IV fluid therapy and hemodynamic monitoring.
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• Recombinant granulocyte colony stimulating factor could be consid-
ered for use in patients that have received an inadvertent overdose
with a myelosuppressive drug or when profound neutropenia persists
for >1 week.
Strength of recommendation: Strong
26. Once the patient has recovered from the neutropenic episode, and
if further immunosuppressive treatment is required, we suggest a
different drug be used than the drug that caused the neutropenia.
Strength of recommendation: Weak
3.7 | Management of infections in dogs receiving
immunosuppressive drugs
An expanded version of this section, with further commentary and
discussion of underlying evidence, is available in Supporting Informa-
tion Appendix A3.
27. We suggest that the regimen of immunosuppressive drugs may
need to be modified if infections are detected, but doing so
depends on multiple factors, including the severity and nature of
the infection, the severity and stage of treatment of the IMHA,
and the immunosuppressive regimen employed. Clinicians also
should consider that emerging infections may represent the
underlying cause of the immune-mediated disease.
Strength of recommendation: Weak
3.7.1 | Therapeutic drug monitoring
28. If available, we suggest that appropriate TDM be considered in
all cases, particularly in cases with actual or anticipated problems,
including:
 poor response to treatment,
 possible interaction between drugs, and
 emerging secondary infection.
Strength of recommendation: Weak
Rationale
Pharmacokinetic monitoring is available for cyclosporine and lefluno-
mide, and pharmacodynamic monitoring (measuring suppression of T
cell IL-2 synthesis) is available for cyclosporine. A list of centers cur-
rently offering TDM is shown in Supporting Information S4.
3.8 | Approach to relapse
Our recommended approach to investigation and management of
relapses is summarized in Figure 6.
29. We recommend confirming the relapse using standard criteria for
the diagnosis of IMHA (see Consensus Statement on Diagnosis of
Immune-Mediated Hemolytic Anemia in Dogs and Cats32) to
ensure that there is no alternative cause of anemia.
Strength of recommendation: Strong
Rationale
The results of some tests may be affected by previous administration
of immunosuppressive drugs. The clinician should be satisfied that suf-
ficient abnormalities exist to diagnose a relapse, rather than another
cause of anemia, such as gastrointestinal bleeding. Objective data on
frequency of relapse in IMHA are scarce. Retrospective studies with
long-term follow-up suggest a relapse rate of 11%-15%.2,7 The follow-
ing guidelines for management of relapsing IMHA are based on clinical
reasoning and experience of the panel.
30. We recommend assessing the patient for any trigger factors that
could derange immune homeostasis, with particular emphasis on
emerging infection if the relapse occurred while the patient was
still receiving immunosuppressive drugs.
Strength of recommendation: Strong
Rationale
Immune homeostasis may be affected by administration of drugs or
vaccines, onset of inflammatory disease, emerging infection (particu-
larly involving vector-borne agents), and neoplasia.
31. If the relapse occurred before any attempted dose reduction of
the initial prednisone or prednisolone treatment, we suggest
introducing an additional immunosuppressive drug (as described
in recommendation #10). If a dog is already receiving 2 immuno-
suppressive drugs, we suggest performing TDM to ensure ade-
quate drug dosage, as in recommendation #28.
Strength of recommendation: Weak
32. If the relapse occurred during tapering of immunosuppressive
drugs (as described in recommendations #14-16), we suggest
that the dosage of immunosuppressive drugs be increased. If the
relapse manifested as fulminant disease, the initial (previously
successful) induction protocol should be recommenced. If the
relapse manifested as mild disease, the immunosuppressive drug
dose should be increased back to the last dose that the patient
was receiving before the most recent dose reduction.
Strength of recommendation: Weak
33. Once remission has been reestablished, we suggest commencing
the tapering process more gradually than on the previous occa-
sion, as outlined in recommendations #14-16. We suggest that
the time from remission to the first dose reduction be doubled,
and that the time interval between subsequent dose reductions
be doubled.
Strength of recommendation: Weak
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34. If recurrent relapses occur despite the measures described above,
we suggest that lifelong immunosuppressive treatment may be
required, aiming to maintain remission using the lowest possible
dosage of immunosuppressive drug.
Strength of recommendation: Weak
35. In dogs requiring continuous immunosuppressive treatment, or
suffering repeated relapses, we suggest that splenectomy be
considered, provided that infection with vector-borne agents has
been exhaustively excluded.
Strength of recommendation: Weak
Rationale
Splenectomy has been evaluated in 2 retrospective case series for relaps-
ing or refractory IMHA. One study of 6 dogs showed 100% survival at
12 months postsplenectomy, with decreased or absent medication
F IGURE 6 Flow diagram showing
recommended approach for management
of relapse in dogs with immune-mediated
hemolytic anemia (IMHA). IVIG,
intravenous immunoglobulin; TDM,
therapeutic drug monitoring. Various
outcomes make reference to Consensus
Summary Statement #33, to which the
reader is referred for further information
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requirement after surgery compared to before.106 In another study of
10 dogs, 9 were alive 30 days postsplenectomy and the authors reported
decreased transfusion requirements and increased PCV after surgery
compared to before.107 However, neither study enrolled a control group
that did not undergo splenectomy, so it is impossible to determine
whether splenectomy improved outcome.
Vector-borne agents may be latent in dogs with IMHA or acquired
through blood transfusion. We are not aware of publications docu-
menting infection in IMHA patients postsplenectomy, but this may
reflect infrequent occurrence of splenectomy, short follow-up times,
or both. Splenectomy per se is a procedure associated with a low risk
of short-term complications,106,107 but we recommend that immuno-
suppressive and antithrombotic medications be stopped or their dos-
age decreased to a minimum before surgery is undertaken. Further
recommendations regarding screening for vector-borne agents are pro-
vided in the accompanying Consensus Statement onDiagnosis of Immune-
MediatedHemolytic Anemia inDogs andCats.32
36. If there appeared to be a temporal association between estrus cycle
and relapse, we suggest that intact female dogs be spayed once
they have been weaned off, or onto the lowest effective dose of,
immunosuppressive drug(s). Similarly, if there appeared to be a tem-
poral association between pregnancy and relapse, we suggest that
the bitch not be bred again, or be spayed when weaned off, or onto
the lowest effective dose of, immunosuppressive drug(s).
Strength of recommendation: Weak
Rationale
This recommendation is based on the clinical experience of the panel.
Affected dogs also should not be receiving thromboprophylactic drugs
at the time of surgery.
3.9 | Emerging immunomodulatory treatments for
dogs with IMHA
An expanded version of this section, with further commentary and
discussion of underlying evidence, is available in Supporting Informa-
tion Appendix A4.
37. The use of a number of other treatments, including therapeutic plas-
mapheresis, liposomal clodronate, hyperbaric oxygen therapy, and
melatonin, has been reported, scientifically, anecdotally, or in a small
number of dogs with IMHA, but we suggest further investigation is
required to determine whether these treatments are effective, and to
establish how their use should be integratedwith other treatments.
Strength of recommendation: Weak
3.10 | Antithrombotic treatment
The terms “thromboprophylaxis” and “antithrombotics” encompass both
antiplatelet drugs, designed to inhibit platelet function (primary hemosta-
sis), and anticoagulant drugs, designed to inhibit the activity of clotting
factors (secondary hemostasis). We draw specific distinctions between
antiplatelet and anticoagulant drugs. An outline of our recommendations
relating to antithrombotic treatment is shown in Figure 7. Additional guid-
ance on the use of antithrombotic drugs in dogs is provided in the CURA-
TIVE guidelines.108
38. We recommend that thromboprophylaxis be provided for all
dogs with IMHA, except those with severe thrombocytopenia
(platelet count <30 000/μL).
Strength of recommendation: Strong
Rationale
A substantial body of evidence indicates that IMHA in dogs is associ-
ated with an increased risk of thrombosis,9,15,109–112 and that throm-
botic disease is a leading cause of morbidity and mortality in dogs
with IMHA.10,113,114 The pathophysiology of thrombosis in IMHA is
complex,8,42 involving endothelial activation,42 intravascular tissue
factor expression,115 procoagulant microparticle generation,116 platelet
activation,117 and an imbalance of pro- and anticoagulant factors.118–120
Previous studies have suggested that thromboprophylaxis may be partic-
ularly important in dogs with intravascular hemolysis, autoagglutination,
marked leukocytosis, and increased liver enzyme activities.9,10,53,121
Dogs with IMHA receiving high dosages of glucocorticoids,122,123
and those receiving IVIG,59,60,124 also may be at increased risk of
thrombosis.
We have specified an arbitrary platelet concentration of 30 000/
μL, below which we would not recommend that antithrombotics be
administered, particularly if an antiplatelet drug is selected, because we
considered that the risk of spontaneous hemorrhage is increased below
this threshold. In the context of IMHA, some authors have classified
severe thrombocytopenia as <50 000/μL,17 whereas others have used
<15 000/μL.125 We recommend that antithrombotic drugs only be
F IGURE 7 Algorithm showing recommended approach to
selection of antithrombotic drugs for dogs with immune-mediated
hemolytic anemia (IMHA). LMW, low molecular weight
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administered to dogs with platelet counts >30 000/μL, because in
these patients the thrombocytopenia is most likely consumptive.126,127
39. We suggest that thromboprophylaxis be initiated at the time of
diagnosis and continued until the patient is in remission and no
longer receiving prednisone or prednisolone.
Strength of recommendation: Weak
Rationale
The maximum risk period for mortality associated with IMHA appears
to be the first 2 weeks after initiation of treatment.54 This period rep-
resents the phase when pathophysiologic risk factors for thrombosis
are maximal, likelihood of transfusion is highest, and any prothrombo-
tic effect of immunosuppressive medications is greatest, if related to
dosage. The risk of hemorrhage from recommended antithrombotic
dosages is likely to be small.128 As the disease process responds to
immunosuppression, the likelihood of thrombosis may diminish, but
the continued use of immunosuppressive medications may generate
ongoing thrombotic risk.129,130 Some dogs may require lifelong low
doses of glucocorticoids to maintain remission. We suggest that
thromboprophylaxis be discontinued if such dogs have been in remis-
sion for 6 months and no other risk factors exist.
40. Based on the pathophysiology of venous thromboembolism com-
monly encountered in dogs with IMHA, we suggest that a regimen
incorporating anticoagulants may be preferred for thromboprophy-
laxis, particularly during the first 2 weeks after diagnosis. The avail-
able anticoagulants may be used alone or combined with antiplatelet
drugs. If treatment with an anticoagulant, and its associated
monitoring, is not available or feasible, we suggest administra-
tion of antiplatelet drugs in preference to no antithrombo-
tic drug.
Strength of recommendation: Weak
Rationale
Thrombosis in IMHA predominantly affects the venous system, where
thrombi form under low-shear conditions.131 Such thrombi typically
are rich in fibrin, and their formation is less dependent upon platelet
number or function, providing a rationale for administration of antico-
agulant drugs.15,121,132 Although platelet activation can be detected in
dogs with IMHA, this phenomenon probably occurs secondary to
pathologic tissue factor-mediated thrombin generation, rather than as
a primary event.42,133,134 Nevertheless, the cell-based model of hemo-
stasis posits that platelets are integral to hemostasis in vivo.135,136
There is thus a rationale for the use of antiplatelet drugs in venous
thrombosis.132,137–140 Experimental data support this proposition to
some degree,141 and evidence in humans suggests that antiplatelet
drugs do decrease the risk of venous thrombosis.142–145 However,
this should be viewed in the context of the substantial body of evi-
dence in humans supporting administration of anticoagulants as first
line prophylactic drugs for venous thrombosis.146–148
41. We suggest the administration of unfractionated heparin (UFH)
with individual dose adjustment (using an anti-Xa assay) in pref-
erence to other drugs. This drug should not be used without indi-
vidual dose adjustment. If this is not available or feasible, we
suggest administering injectable low-molecular-weight heparins
or direct PO Xa inhibitors. When using injectable low-molecular-
weight heparins, we suggest individual dose adjustment (using an
anti-Xa assay) may be useful to achieve a therapeutic dose.
Suggested starting dosages for these drugs are:
 Unfractionated heparin (IV): 100 U/kg bolus, then 900 U/kg/24 h
 Unfractionated heparin (SC): 150-300 U/kg q6h
 Dalteparin (SC): 150-175 U/kg q8h
 Enoxaparin (SC): 0.8-1.0 mg/kg q6-8h
 Rivaroxaban (PO): 1-2 mg/kg q24h
Strength of recommendation: Weak
Rationale
Insufficient evidence is available to make strong recommendations on
the choice of anticoagulant in IMHA (Table 5 and Figure 8). The stron-
gest evidence supports the use of individually dose-adjusted UFH.26
Other anticoagulants including enoxaparin and rivaroxaban appear to
be safe and may be efficacious,27,55 but RCTs are lacking. In a pro-
spective study of UFH use in dogs with IMHA, dosages of 300 U/kg
SC q6h generated anti-Xa activities below the target ranges in more
than half of the dogs.149 A subsequent RCT of dogs with IMHA com-
pared UFH treatment administered at constant dose with individually
dose-adjusted UFH treatment based on anti-Xa monitoring.26 This
study demonstrated significantly longer survival in dogs given individ-
ually adjusted doses, with only 1/8 non-survivors compared to 6/7
non-survivors in the constant dose group (Table 5). Dosages of UFH
of 150-566 U/kg q6h were required to achieve anti-Xa activities
between 0.35 and 0.7 U/mL.26 However, this study enrolled a small
number of dogs and provided incomplete information on masking and
randomization (Figure 8). Indeed, the study has a fragility index of only
2,13 meaning that the outcome of only 2 cases would need to change
to lose statistical significance, and suggesting that these findings war-
rant confirmation. One further RCT found no difference in survival in
dogs treated with rivaroxaban compared with dogs treated with clopi-
dogrel and ultra-low-dose aspirin (Table 5), but this study was under-
powered and does not demonstrate equivalency of interventions.27
Various publications have determined pharmacokinetics of low-
molecular-weight heparins in dogs.150–152 Considerable variation in
anti-Xa activities has been documented and some uncertainty remains
about the efficacy of enoxaparin in some breeds of dog.55,152,153 Dal-
teparin does appear efficacious in dogs for venous and arterial throm-
boprophylaxis.154,155 The level of anti-Xa activity that confers
thromboprophylaxis remains uncertain, but, given the variation in phar-
macokinetics and that it is efficacy, monitoring anti-Xa activity may be
justifiable. We believe it is reasonable to target 0.5-1.0 U/mL anti-Xa
activity for both enoxaparin and dalteparin.156
Anti-Xa monitoring is not widely available to veterinarians. If an
anti-Xa assay is not available, then it is reasonable to consider the
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activated clotting time, activated partial thromboplastin time (aPTT),
thrombin generation, or viscoelastic tests to monitor anticoagulant
treatment.153,156–164 Nomograms for adjustment of UFH treatment
using aPTT and thromboelastographic assays have been proposed,
but are currently only available in abstract form.165,166 The original
derivation of UFH aPTT prolongation targets was performed using
thrombotic models in dogs.167 Subsequently, these aPTT targets were
demonstrated to correlate with recommended 0.35-0.70 U/mL anti-
Xa activity targets in humans.168,169 These activity targets protect
against thrombosis in people,146,170 and are the basis for the currently
recommended targets for anti-Xa activity in dogs. However, we rec-
ognize that there is limited evidence of efficacy for these targets
against patient-centered outcomes (eg, prevention of documented
thrombosis, mortality) in dogs with clinical disease. Higher dosages
than the initial starting dosages listed above may be necessary to
attain these anti-Xa activity targets in dogs with diseases that predis-
pose to thrombosis.26,156 Initiating antithrombotic treatment at these
dosages and increasing the dose incrementally based on individual
monitoring may provide a margin of safety for patients against hem-
orrhagic complications. In our experience, many patients will require
such dose escalation.
42. If antiplatelet drugs are administered, we suggest that clopidogrel
be used in preference to aspirin. We suggest that clopidogrel be
administered at a dosage of 1.1-4.0 mg/kg PO q24h. A single PO
loading dose (eg, double the maintenance dosage or up to
10 mg/kg) may be useful for obtaining therapeutic plasma
concentrations rapidly. If aspirin is selected as an antiplatelet
drug, it should be administered at a dosage of 1-2 mg/kg
q24h and could be combined with clopidogrel.
Strength of recommendation: Weak
Rationale
Clopidogrel may be efficacious for arterial thromboprophylaxis in
dogs.171–175 However, insufficient evidence is available to judge the
efficacy of clopidogrel for prevention of venous thrombosis in dogs.
Aspirin is a safe and effective drug for prevention of arterial thrombo-
sis in dogs,176 but insufficient evidence is available to judge the effi-
cacy of aspirin for the prevention of venous thrombosis in dogs.
Thirty percent or more of healthy dogs fail to respond to low dose
aspirin,177,178 and a minimum dosage of 2.0-5.0 mg/kg PO q12-24h is
required for reliable platelet inhibition in responders.179–181 Studies
have demonstrated the failure of 1.0 and 3.5 mg/kg PO q12h of aspi-
rin to reliably inhibit canine platelets.182,183 Although aspirin at a dos-
age of 0.5 mg/kg q24h in combination with glucocorticoids appears
safe,184 aspirin dosages ≥2 mg/kg administered to dogs receiving
concurrent prednisolone may be associated with increased gastroin-
testinal bleeding.185
One retrospective study of dogs with IMHA suggested those
receiving ultra-low-dose aspirin had a survival benefit over those
dogs receiving heparin (Table 5).7 However, this study is limited by
less rigorous inclusion criteria and is confounded by lack of controlT
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for illness severity (Figure 8). Other retrospective data (published only
as an abstract186) suggest that individualized heparin dosing may pro-
vide superior thromboprophylaxis compared to aspirin. Among the
antiplatelet drugs, 1 RCT detected no difference in mortality in dogs
treated with ultra-low-dose aspirin, clopidogrel, or both (Table 5).11
However, this study appears to have been underpowered and may
have used an inappropriate statistical test for comparison of survival
between groups (Figure 8).
3.11 | Supportive care and antimicrobial treatment
for dogs with IMHA
An expanded version of this section, with further commentary and
discussion of underlying evidence, is available in Supporting Informa-
tion Appendix A5.
43. We suggest that gastroprotectant treatment is administered only
to dogs with IMHA with either:
 ongoing evidence of gastrointestinal ulceration (eg, melena), or
 known or potential risk factors for development of ulcers and
gastrointestinal bleeding.
Strength of recommendation: Weak
44. Where gastroprotectant treatment is indicated, we recommend
administration of a proton pump inhibitor for a defined period of
time, with discontinuation as soon as risk factors for ulcer devel-
opment or bleeding abate.
Strength of recommendation: Strong
45. We recommend assessing the risk of infection with hemotropic
or vector-borne pathogens in individual dogs presenting with
IMHA, depending on their geographic location, lifestyle, and
travel or importation history. In dogs considered to have a high
risk of infection, we recommend empirical administration of
appropriate antimicrobial drugs while awaiting the results of
definitive diagnostic tests for these pathogens. Such definitive
diagnostic tests should be the basis of longer term antimicrobial
treatment recommendations.
Strength of recommendation: Strong
3.12 | Monitoring of dogs in remission from IMHA
46. When a dog has recovered fully from IMHA and has stopped
receiving all treatment, we suggest continued monitoring of
CBCs or other hematologic measurements for 4 weeks to con-
firm treatment-free remission. Beyond this period of time, we
suggest that regular CBCs or other hematologic measurements
are not required. Nevertheless, owners should be encouraged to
monitor for clinical signs associated with anemia and to contact a
veterinarian immediately if these are observed.
Strength of recommendation: Weak
Rationale
Monitoring of dogs with IMHA after cessation of treatment is poorly
described in the literature. However, in our experience, relapses tend
to occur acutely, so routine CBCs would seem to be of little or no use
in predicting them once the dog has recovered fully.
3.13 | Recommendations for future research
Further investigation of the pathogenesis and heterogeneity of IMHA
in dogs is likely to identify novel biomarkers of disease activity and
prognosis, as well as avenues for more specific and targeted treatment.
Such studies also could explore the prevalence and extent of thrombo-
sis in dogs with IMHA. Prospective, randomized, multicenter clinical tri-
als are required to address a number of questions, including whether
the addition of a second drug improves outcome in all, or only a subset
of, patients; whether 1 drug is superior to another as an adjunct to glu-
cocorticoids; and, whether 1 thromboprophylactic regimen is superior
F IGURE 8 Results of evidence quality
assessment for studies investigating the
use of antithrombotic drugs in dogs with
immune-mediated hemolytic anemia
(IMHA). RCT, randomized controlled trial
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to another. Intrinsic to successful treatment is the effective monitoring
of disease outcomes. Therapeutic drug monitoring is recognized as a
useful tool to optimize drug dosage, but evidence-based reference tar-
gets for pharmacokinetic and pharmacodynamic assays currently are
lacking. A number of new and emerging treatments promise to deliver
more rapid targeted control of aggressive autoimmune responses, but
further work is required in this area before firm recommendations can
be made. For example, the impact of therapeutic plasmapheresis on
patient outcome, and how it should be used in individual patients,
remains to be established.
Comparison of results derived from different studies will be facili-
tated by consistent reporting of diagnostic criteria, treatment regi-
mens, and outcome measures. We therefore have developed a set of
reporting guidelines for future studies of dogs with IMHA to improve
consistency among reports (Supporting Information Appendix A6).
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